Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Backs Price Regulator In Ranbaxy Antibiotic Dispute

This article was originally published in PharmAsia News

Executive Summary

India's government has backed its drug-price regulator's decision to fix the price of Ranbaxy Laboratories' Roscillin (ampicillin trihydrate IP) antibiotic. The action by the Chemicals and Fertilisers Ministry, which was ordered by the Delhi High Court to review Ranbaxy's objection, is considered a setback for Indian drug makers. The ministry's decision is seen as an indication the government has no intention of interfering with its National Pharmaceutical Pricing Authority. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC067890

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel